253 related articles for article (PubMed ID: 16570152)
21. Severe skin reaction to imatinib in a case of Philadelphia-positive acute lymphoblastic leukemia.
Sanchez-Gonzalez B; Pascual-Ramirez JC; Fernandez-Abellan P; Belinchon-Romero I; Rivas C; Vegara-Aguilera G
Blood; 2003 Mar; 101(6):2446. PubMed ID: 12609964
[No Abstract] [Full Text] [Related]
22. Imatinib-induced tumor lysis syndrome: report of a case and review of the literature.
Chang H; Shih LY
Chang Gung Med J; 2008; 31(5):510-4. PubMed ID: 19097599
[TBL] [Abstract][Full Text] [Related]
23. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
Ottmann OG; Wassmann B; Pfeifer H; Giagounidis A; Stelljes M; Dührsen U; Schmalzing M; Wunderle L; Binckebanck A; Hoelzer D;
Cancer; 2007 May; 109(10):2068-76. PubMed ID: 17429836
[TBL] [Abstract][Full Text] [Related]
24. Optimal central nervous system prophylaxis in Philadelphia chromosome-positive acute lymphoblastic leukemia: collateral damage in the imatinib era?
Bassan R
Leuk Lymphoma; 2011 Jul; 52(7):1164-5. PubMed ID: 21612380
[No Abstract] [Full Text] [Related]
25. Syndrome of inappropriate secretion of antidiuretic hormone associated with imatinib.
Liapis K; Apostolidis J; Charitaki E; Panitsas F; Harhalakis N; Nikiforakis E
Ann Pharmacother; 2008 Dec; 42(12):1882-6. PubMed ID: 19017824
[TBL] [Abstract][Full Text] [Related]
26. Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib.
Woo SM; Huh CH; Park KC; Youn SW
J Dermatol; 2007 Oct; 34(10):724-6. PubMed ID: 17908148
[No Abstract] [Full Text] [Related]
27. [Bone marrow necrosis with a septic picture preliminary to subtype L3 acute lymphoblastic leukemia].
Martín Noya A; García Luaces M; Picabea L; Parody R; Rodríguez Fernández JM
Sangre (Barc); 1989 Dec; 34(6):518-20. PubMed ID: 2629129
[No Abstract] [Full Text] [Related]
28. Imatinib-induced erythrodermia in a patient with chronic myeloid leukemia.
Oztas P; Erbasi S; Lenk N; Polat M; Han O; Artuz F; Alli N
Acta Derm Venereol; 2006; 86(2):174-5. PubMed ID: 16648930
[No Abstract] [Full Text] [Related]
29. Post-fracture excessive callus formation in a child on imatinib therapy.
Ramzan M; Verma R; Chopra YR; Yadav SP
Pediatr Blood Cancer; 2013 Dec; 60(12):2087-8. PubMed ID: 24038762
[No Abstract] [Full Text] [Related]
30. Bone marrow necrosis preceding infantile acute lymphoblastic leukaemia.
Eusni RM; Hamidah Hussin N; Zarina AL; Rahman J
Malays J Pathol; 2007 Dec; 29(2):113-7. PubMed ID: 19108404
[TBL] [Abstract][Full Text] [Related]
31. [Bone marrow necrosis and type L3 acute lymphoblastic leukemia. An infrequent association].
Gil González I; San José Díez J; Tortosa Cavero JL; Velasco Fernández C
Sangre (Barc); 1989 Apr; 34(2):157-8. PubMed ID: 2756453
[No Abstract] [Full Text] [Related]
32. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
33. Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study.
Piccaluga PP; Malagola M; Rondoni M; Arpinati M; Paolini S; Candoni A; Fanin R; Messa E; Pirrotta MT; Lauria F; Visani G; Alberti D; Rancati F; Vinaccia V; Russo D; Saglio G; Baccarani M; Martinelli G
Haematologica; 2007 Dec; 92(12):1721-2. PubMed ID: 18056005
[TBL] [Abstract][Full Text] [Related]
34. Prediction of risk of disease recurrence by genome-wide cDNA microarray analysis in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy.
Zembutsu H; Yanada M; Hishida A; Katagiri T; Tsuruo T; Sugiura I; Takeuchi J; Usui N; Naoe T; Nakamura Y; Ohno R
Int J Oncol; 2007 Aug; 31(2):313-22. PubMed ID: 17611687
[TBL] [Abstract][Full Text] [Related]
35. Pneumatosis intestinalis and imatinib mesylate.
O'Rafferty C; McElligott F; Storey L; O'Marcaigh A; Smith O
Ann Hematol; 2014 Oct; 93(10):1783-4. PubMed ID: 24647683
[No Abstract] [Full Text] [Related]
36. Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro.
Kircher B; Schumacher P; Petzer A; Hoflehner E; Haun M; Wolf AM; Nachbaur D; Gastl G
Eur J Haematol; 2009 Jul; 83(1):48-56. PubMed ID: 19226363
[TBL] [Abstract][Full Text] [Related]
37. [Nephrotoxicidad for imatinib].
Díaz Rodríguez C; Vasco B
Nefrologia; 2003; 23(3):273-4. PubMed ID: 12891946
[No Abstract] [Full Text] [Related]
38. Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy.
Yanada M; Takeuchi J; Sugiura I; Akiyama H; Usui N; Yagasaki F; Nishii K; Ueda Y; Takeuchi M; Miyawaki S; Maruta A; Narimatsu H; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
Haematologica; 2008 Feb; 93(2):287-90. PubMed ID: 18223280
[TBL] [Abstract][Full Text] [Related]
39. Imatinib: new indication. New indications, but not robust evidence.
Prescrire Int; 2008 Jun; 17(95):91-4. PubMed ID: 18623899
[TBL] [Abstract][Full Text] [Related]
40. Transient trisomy 8 abnormality in Philadelphia-negative cells during imatinib mesylate treatment of chronic myelogenous leukemia.
Kim M; Lee S; Jung CK; Lim J; Cho SG; Kim DW; Kim Y; Han K; Min WS; Kim CC
Int J Lab Hematol; 2008 Dec; 30(6):508-12. PubMed ID: 18983302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
